Biotech M&A activity has accelerated sharply in 2026, with deal value reaching $130 billion in H1 alone. Four biotech companies—Abivax, Iovance Biotherapeutics, Viking Therapeutics, and BioCryst Pharmaceuticals—are highlighted as potential acquisition targets due to their differentiated late-stage assets and strategic positioning in high-growth therapeutic areas including immunology, oncology, obesity, and rare diseases.

The ulcerative colitis market is experiencing significant growth with emerging therapies addressing unmet needs in moderate-to-severe disease. The market, valued at approximately USD 9.4 billion in 2025, is projected to expand at a CAGR of 7.6% through 2036. Five promising late-stage candidates—Obefazimod (Abivax), Tulisokibart (Merck), Afimkibart (Roche), Icotrokinra (J&J/Protagonist), and Duvakitug (Teva/Sanofi)—are reshaping the treatment landscape with novel mechanisms targeting IL-23 and TL1A pathways, while established biologics and oral therapies continue to maintain market presence.

The article highlights three biotech and semiconductor stocks that have more than doubled in the past 12 months but may have further upside potential. Abivax is advancing obefazimod for ulcerative colitis with strong clinical results. Krystal Biotech is generating strong revenue growth from its approved DEB treatment Vyjuvek with significant market expansion opportunities. Marvell Technology is capitalizing on AI infrastructure spending demand for custom chips as an alternative to Nvidia's GPUs.

Abivax SA resumed trading of its ordinary shares on Euronext Paris on July 1, 2026, following a temporary halt. The company announced the pricing of an oversubscribed and upsized public offering of American Depositary Shares, increased from the previously announced $600M to $800M at $125.00 per share.

Abivax SA announced a temporary suspension of its ordinary shares trading on Euronext Paris starting July 1, 2026 at market opening. The suspension is related to the company's public offering of American Depositary Shares (ADS) in the United States to confirm investor allocations and announce final offering terms. Trading is expected to resume around 15:30 CEST the same day.

Abivax SA announced a temporary trading halt of its ordinary shares on Euronext Paris effective July 1, 2026, from market opening at 9:00 a.m. CEST. The halt is in connection with the company's public offering of American Depositary Shares in the United States to allow for allocation confirmation and pricing announcement. Trading is expected to resume at approximately 3:30 p.m. CEST the same day.

Abivax stock rose 3.46% on Thursday despite concerns following the release of Phase 3 trial data for obefazimod in ulcerative colitis. While the drug met primary endpoints with remission rates exceeding 50%, reported cancer cases during the trial have raised safety concerns among investors. The stock trades below its moving averages, with momentum indicators suggesting weakness.

Abivax, a French biotech company, saw its stock surge 1,000% over the past year following strong phase 3 results for obefazimod, a non-immunosuppressant ulcerative colitis treatment. However, recent maintenance trial data revealed safety concerns including cancer cases, causing a sharp stock decline. The author argues the market may be overreacting, noting that cancer cases were mostly in older patients and may be unrelated to the drug, while obefazimod still shows strong efficacy and oral convenience advantages.

Abivax and Viking Therapeutics are two biotech companies that could potentially double in value by 2030 if their leading drug candidates succeed in clinical trials and regulatory approval. Abivax is developing obefazimod for ulcerative colitis, while Viking Therapeutics is advancing VK2735 for weight loss treatment. Both stocks carry significant risk due to their clinical-stage status and lack of approved products.

The Crohn's Disease therapeutics market across eight major markets is projected to grow from $9.5 billion to $13.8 billion by 2032 at a CAGR of 3.9%, driven by approvals of 8 pipeline, generic, and biosimilar therapies. Novel mechanisms of action and emerging treatments will reshape the competitive landscape, with key opportunities in strategic licensing and partnerships.

Abivax CEO Marc de Garidel downplayed acquisition rumors and indicated the company plans to pursue equity and debt financing after releasing key Phase 3 trial data for obefazimod in late Q2 2026. With $614.42 million in cash providing runway into Q4 2027, the French biotech aims to strengthen its financial position ahead of potential FDA approval and commercialization, while seeking commercial partners for markets outside the U.S.

Abivax and Nektar Therapeutics are clinical-stage biotech companies with promising drug candidates that could make them attractive acquisition targets. Abivax is developing obefazimod for inflammatory diseases with phase 3 trial data expected in Q2, while Nektar's rezpegaldesleukin shows strong potential for eczema treatment. Both companies have sufficient funding and could be acquired by major pharmaceutical companies at premium valuations.